- Home
- NUVL vs APA Comparison
NUVL vs APA Comparison
Compare NUVL & APA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- APA
- Stock Information
- Founded
- NUVL 2017
- APA 1954
- Country
- NUVL United States
- APA United States
- Employees
- NUVL N/A
- APA N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- APA Oil & Gas Production
- Sector
- NUVL Health Care
- APA Energy
- Exchange
- NUVL Nasdaq
- APA Nasdaq
- Market Cap
- NUVL 5.6B
- APA 5.6B
- IPO Year
- NUVL 2021
- APA N/A
- Fundamental
- Price
- NUVL $75.00
- APA $19.86
- Analyst Decision
- NUVL Strong Buy
- APA Hold
- Analyst Count
- NUVL 8
- APA 17
- Target Price
- NUVL $115.50
- APA $23.38
- AVG Volume (30 Days)
- NUVL 452.9K
- APA 7.4M
- Earning Date
- NUVL 08-07-2025
- APA 07-30-2025
- Dividend Yield
- NUVL N/A
- APA 5.03%
- EPS Growth
- NUVL N/A
- APA N/A
- EPS
- NUVL N/A
- APA 2.76
- Revenue
- NUVL N/A
- APA $10,148,000,000.00
- Revenue This Year
- NUVL N/A
- APA N/A
- Revenue Next Year
- NUVL N/A
- APA N/A
- P/E Ratio
- NUVL N/A
- APA $7.20
- Revenue Growth
- NUVL N/A
- APA 24.91
- 52 Week Low
- NUVL $55.54
- APA $13.58
- 52 Week High
- NUVL $113.51
- APA $33.41
- Technical
- Relative Strength Index (RSI)
- NUVL 48.73
- APA 65.58
- Support Level
- NUVL $76.42
- APA $20.24
- Resistance Level
- NUVL $78.94
- APA $21.34
- Average True Range (ATR)
- NUVL 2.71
- APA 0.79
- MACD
- NUVL -0.34
- APA 0.20
- Stochastic Oscillator
- NUVL 31.73
- APA 78.19
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About APA APA Corporation
APA Corp is an independent exploration and production company. It develops, and produces crude oil, natural gas, and natural gas liquids. The Company's business has oil and gas operations in three geographic areas: the United States (U.S.), Egypt, and offshore the U.K. in the North Sea (North Sea). APA also has active development, exploration, and appraisal operations ongoing in Suriname, as well as exploration interests in Uruguay, Alaska, and other international locations.